Sarepta Therapeutics Inc (SRPT)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	260,774	129,402	62,222	34,060	-520,098	-661,775	-885,019	-1,098,527	-689,963	-710,546	-502,035	-355,701	-418,948	-485,544	-634,040	-703,081	-553,065	-599,572	-529,269	-654,698
Revenue (ttm)	US$ in thousands	1,901,979	1,640,348	1,504,993	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496
Pretax margin		13.71%	7.89%	4.13%	2.43%	-41.83%	-59.89%	-88.20%	-112.59%	-73.95%	-81.11%	-60.11%	-46.45%	-59.69%	-75.21%	-105.66%	-122.63%	-102.40%	-121.11%	-117.57%	-160.66%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $260,774K ÷ $1,901,979K
= 13.71%

Sarepta Therapeutics Inc's pretax margin experienced a significant improvement over the data provided. From March 31, 2023, where it was at -112.59%, the pretax margin gradually improved, changing to -88.20% by June 30, 2023, and further increasing to -59.89% by September 30, 2023. This positive trend continued, with the pretax margin reaching -41.83% by December 31, 2023. Notably, by March 31, 2024, Sarepta Therapeutics Inc achieved a positive pretax margin of 2.43%, marking a turnaround in profitability. This positive performance was maintained and further improved in subsequent periods, with the pretax margin reaching 13.71% by December 31, 2024. This turnaround indicates an improvement in the company's ability to generate profits before accounting for income taxes, reflecting positively on its operational efficiency and financial management.